tetano
Editor, Senior Moderator
Allergy Asthma Clin Immunol
. 2021 Jan 6;17(1):5.
doi: 10.1186/s13223-020-00509-y.
Asthma and COVID-19: a systematic review
Nat?lia F Mendes[SUP] 1 2 [/SUP], Carlos P Jara[SUP] 1 2 [/SUP], Eli Mansour[SUP] 3 [/SUP], Eliana P Ara?jo[SUP] 1 2 [/SUP], Licio A Velloso[SUP] 4 5 [/SUP]
Affiliations
Abstract
Background: Severe coronavirus disease-19 (COVID-19) presents with progressive dyspnea, which results from acute lung inflammatory edema leading to hypoxia. As with other infectious diseases that affect the respiratory tract, asthma has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven.
Methods: Here, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition, which could indicate its potential involvement in disease progression.
Results: We found 372 articles describing the underlying diseases of 161,271 patients diagnosed with COVID-19. Asthma was reported as a premorbid condition in only 2623 patients accounting for 1.6% of all patients.
Conclusions: As the global prevalence of asthma is 4.4%, we conclude that either asthma is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.
Keywords: Allergy; Coronavirus; Lung; Respiratory insufficiency; SARS-CoV-2.
. 2021 Jan 6;17(1):5.
doi: 10.1186/s13223-020-00509-y.
Asthma and COVID-19: a systematic review
Nat?lia F Mendes[SUP] 1 2 [/SUP], Carlos P Jara[SUP] 1 2 [/SUP], Eli Mansour[SUP] 3 [/SUP], Eliana P Ara?jo[SUP] 1 2 [/SUP], Licio A Velloso[SUP] 4 5 [/SUP]
Affiliations
- PMID: 33407838
- DOI: 10.1186/s13223-020-00509-y
Abstract
Background: Severe coronavirus disease-19 (COVID-19) presents with progressive dyspnea, which results from acute lung inflammatory edema leading to hypoxia. As with other infectious diseases that affect the respiratory tract, asthma has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven.
Methods: Here, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition, which could indicate its potential involvement in disease progression.
Results: We found 372 articles describing the underlying diseases of 161,271 patients diagnosed with COVID-19. Asthma was reported as a premorbid condition in only 2623 patients accounting for 1.6% of all patients.
Conclusions: As the global prevalence of asthma is 4.4%, we conclude that either asthma is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.
Keywords: Allergy; Coronavirus; Lung; Respiratory insufficiency; SARS-CoV-2.